Breaking News

VSY Biotech Develops TR-C 19 Candidate to Treat COVID-19

Studies have shown that TR-C 19 can neutralize the virus isolated under lab conditions, clinical trials are underway.

By: Contract Pharma

Contract Pharma Staff

VSY Biotechnology GmbH has developed a new drug candidate, TR-C 19, to treat COVID-19. Studies have shown that TR-C 19 can neutralize the virus isolated under lab conditions. The drug is under review for use on voluntary COVID-19 patients and clinical trials. Health authorities have accelerated their evaluation of TR-C 19 considering the public health emergency conditions. Dr. Ercan Varlibas, the Chairman of the Board of Directors of VSY Biotechnology GmbH said, “At VSY Biotechnology, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters